NCT04121858 is a NA clinical trial of Brain Safe App in Alzheimer Disease, sponsored by Indiana University.

Who is sponsoring NCT04121858?

NCT04121858 is sponsored by Indiana University.

What drugs are being tested in NCT04121858?

Interventions in NCT04121858: Brain Safe App, Attention Control App.

What condition does NCT04121858 study?

NCT04121858 studies Alzheimer Disease, Dementia.

Is NCT04121858 still recruiting?

NCT04121858 is currently completed. Last updated 13 March 2025.

Last reviewed 2025-03-13 · How we verify

NCT04121858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease

Completed NA Last updated 13 March 2025

What this trial tests

NA trial testing Brain Safe App in Alzheimer Disease in 706 participants. Completed in 27 February 2025.

Timeline

16 October 2019

Primary endpoint
27 February 2025

27 February 2025

Quick facts

Lead sponsor	Indiana University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	706
Start date	16 October 2019
Primary completion	27 February 2025
Estimated completion	27 February 2025
Sites	2 locations across United States

Drugs / interventions tested

Brain Safe App
Attention Control App

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →
Dementia — all drugs for Dementia →

Sponsor

Indiana University

Who can join

60 and older, any sex, with Alzheimer Disease or Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Going Remote-Demonstration and Evaluation of Remote Technology Delivery and Usability Assessment With Older Adults: Survey Study.
Hill JR, Harrington AB, Adeoye P, Campbell NL, et al · · 2021 · cited 16× · PMID 33606655 · DOI 10.2196/26702
Deprescribing anticholinergics in primary care older adults: Experience from two models and impact on a continuous measure of exposure.
Campbell NL, Pitts C, Corvari C, Kaehr E, et al · · 2022 · cited 7× · PMID 36620097 · DOI 10.1002/jac5.1682
Reducing anticholinergic medication exposure among older adults using consumer technology: Protocol for a randomized clinical trial.
Abebe E, Campbell NL, Clark DO, Tu W, et al · · 2021 · cited 4× · PMID 33773639 · DOI 10.1016/j.sapharm.2020.10.010

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other Indiana University trials

Trials by the same sponsor.

NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04121858 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 13 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04121858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing